Chanavaz C, Tirel O, Wodey E, Bansard J Y, Senhadji L, Robert J C, Ecoffey C
Department of Anesthesiology and Surgical Intensive Care, Pediatric and Physiology Hôpital Pontchaillou, Université de Rennes 1, Rennes, France.
Br J Anaesth. 2005 Jan;94(1):74-9. doi: 10.1093/bja/aeh293. Epub 2004 Oct 14.
Remifentanil is known to cause bradycardia and hypotension. We aimed to characterize the haemodynamic profile of remifentanil during sevoflurane anaesthesia in children with or without atropine.
Forty children who required elective surgery received inhalational induction of anaesthesia using 8% sevoflurane. They were allocated randomly to receive either atropine, 20 microg kg(-1) (atropine group) or Ringer's lactate (control group) after 10 min of steady-state 1 MAC sevoflurane anaesthesia (baseline). Three minutes later (T0), all children received remifentanil 1 microg kg(-1) injected over a 60 s period, followed by an infusion of 0.25 microg kg(-1) min(-1) for 10 min then 0.5 microg kg(-1) min(-1) for 10 min. Haemodynamic variables and echocardiographic data were determined at baseline, T0, T5, T10, T15 and T20 min.
Remifentanil caused a significant decrease in heart rate compared with the T0 value, which was greater at T20 than T10 in the two groups: however, the values at T10 and T20 were not significantly different from baseline in the atropine group. In comparison with T0, there was a significant fall in blood pressure in the two groups. Remifentanil caused a significant decrease in the cardiac index with or without atropine. Remifentanil did not cause variation in stroke volume (SV). In both groups, a significant increase in systemic vascular resistance occurred after administration of remifentanil. Contractility decreased significantly in the two groups, but this decrease remained moderate (between -2 and +2 sd).
Remifentanil produced a fall in blood pressure and cardiac index, mainly as a result of a fall in heart rate. Although atropine was able to reduce the fall in heart rate, it did not completely prevent the reduction in cardiac index.
已知瑞芬太尼可导致心动过缓和低血压。我们旨在描述在有或没有阿托品的情况下,瑞芬太尼在小儿七氟醚麻醉期间的血流动力学特征。
40例需要择期手术的儿童接受8%七氟醚吸入诱导麻醉。在1 MAC七氟醚麻醉稳态10分钟(基线)后,他们被随机分配接受阿托品20微克/千克(阿托品组)或乳酸林格液(对照组)。三分钟后(T0),所有儿童接受在60秒内注射1微克/千克的瑞芬太尼,随后以0.25微克/千克·分钟输注10分钟,然后以0.5微克/千克·分钟输注10分钟。在基线、T0、T5、T10、T15和T20分钟测定血流动力学变量和超声心动图数据。
与T0值相比,瑞芬太尼导致心率显著下降,两组在T20时下降幅度大于T10:然而,阿托品组在T10和T20时的值与基线无显著差异。与T0相比,两组血压均显著下降。无论有无阿托品,瑞芬太尼均导致心脏指数显著下降。瑞芬太尼未引起每搏量(SV)变化。两组在给予瑞芬太尼后全身血管阻力均显著增加。两组收缩性均显著下降,但这种下降仍为中度(-2至+2标准差之间)。
瑞芬太尼导致血压和心脏指数下降,主要是由于心率下降。虽然阿托品能够减少心率下降,但它并未完全阻止心脏指数的降低。